van Maldegem, Febe http://orcid.org/0000-0002-2544-544X
Valand, Karishma http://orcid.org/0000-0002-9158-5782
Cole, Megan http://orcid.org/0000-0002-6366-0642
Patel, Harshil http://orcid.org/0000-0003-2707-7940
Angelova, Mihaela http://orcid.org/0000-0002-0495-9695
Rana, Sareena
Colliver, Emma http://orcid.org/0000-0002-1497-0740
Enfield, Katey http://orcid.org/0000-0002-4551-6073
Bah, Nourdine
Kelly, Gavin http://orcid.org/0000-0001-7219-560X
Tsang, Victoria Siu Kwan http://orcid.org/0000-0002-0422-7371
Mugarza, Edurne
Moore, Christopher
Hobson, Philip
Levi, Dina
Molina-Arcas, Miriam
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Downward, Julian http://orcid.org/0000-0002-2331-4729
Article History
Received: 5 March 2021
Accepted: 20 September 2021
First Online: 8 October 2021
Competing interests
: J.D. has acted as a consultant for AstraZeneca, Bayer, Jubilant, Theras, Vividion and Novartis, and has funded research agreements with BMS, Revolution Medicines and Boehringer Ingelheim. C.S. receives grant support from Archer Dx, AstraZeneca, Boehringer Ingelheim and Ono Pharmaceutical; has consulted for AstraZeneca, Bicycle Therapeutics, Celgene, Genentech, GRAIL, GSK, Illumina, Medicxi, MSD, Novartis and the Sarah Cannon Research Institute; receives grant support and has consulted for Bristol Myers Squibb, Pfizer and Roche–Ventana; is an advisory board member and is involved in trials sponsored by AstraZeneca; has stock options in Apogen Biotechnologies, Epic Sciences, GRAIL; and has stock options and is a co-founder of Achilles Therapeutics. The remaining authors declare no competing interests.